HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

J. Lo’s Glow

This article was originally published in The Rose Sheet

Executive Summary

Trial date in trademark infringement case filed against Coty and singer/actress Jennifer Lopez by Glow Industries set for Oct. 21 following Los Angeles federal court Judge Margaret Morrow's decision to deny preliminary injunction barring sale of Lopez's premier fragrance Glow. Los Angeles-based Glow Industries filed lawsuit against Lopez/Coty challenging the use of the name Glow in August (1"The Rose Sheet" Aug. 19, 2002, p. 5). Coty/Lopez filed a counterclaim in October alleging Glow Industries is infringing on a Glow Kit trademark owned by Lopez (2"The Rose Sheet" Oct. 28, 2002, p. 4)...

You may also be interested in...



Coty, Lopez Looking To Secure Exclusive Rights To Glow Name

Coty and singer/actress Jennifer Lopez are seeking to bar Glow Industries from using the Glow trademark for beauty products in an effort to protect the name of Lopez's premier fragrance

Glow Industries Looking To Suppress J. Lo’s Glow With Trademark Suit

Los Angeles-based Glow Industries is challenging Coty's use of the name Glow for its upcoming Jennifer Lopez fragrance with a trademark infringement lawsuit filed in Los Angeles, California federal court Aug. 7

US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios

Forthcoming guidance is expected to describe areas of “low-hanging fruit” and those that are more challenging for use of the expedited pathway, Center for Biologics Evaluation and Research Director Peter Marks said.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS010898

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel